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Gastric ulcer is one of the most common gastrointesti-
nal tract diseases, and has affected humans for centuries.
Helicobactor pylori infection, use of drugs such as non-
steroidal anti-inflammatory drugs (NSAIDs), and stress
are some of the known factors that can cause gastric
ulcers.
Current treatment of gastric ulcer has 2 main ap-
proaches. One is to eliminate the H. pylori bacterium
using antibiotics. The other approach is to use antacids
and/or acid blockers to reduce the level of acid in order
to relieve pain and promote healing of inflammatory
injuries. Proton pump inhibitors such as omeprazole
and cytoprotective drugs including sucralfate and bis-
muth subcitrate are commonly used to treat gastric
ulcer with good results. However, elucidating the de-
tailed mechanisms of gastric ulcer healing remains a
major focus for researchers.
Since gastric ulcer is considered to be an inflam-
matory injury and the healing process involves cell
proliferation, epithelial and fibroblast cell-cell inter-
action, angiogenesis, tissue remodeling and regenera-
tion, many effectors involved in the ulcer healing
process have been studied using both in vivo and in vitro
models.1–3 At present, tumor necrosis factor (TNF)-α,
interleukin (IL)-1β, cyclooxygenases (COX), prosta-
glandins (PGE) and proteases are key players in the
control of the healing processes. The dynamic and
complicated interactions among these effectors are
under extensive investigation. However, the interaction
between the glucocorticoids that are used frequently
in the management of inflammatory diseases and
these effectors is not clear.
Working to dissect the molecular mechanism of gas-
tric protection by modulation of transcription factors
and their relation to proinflammatory cytokines, Lahiri
et al found that treatment of rats with acetic acid-
induced chronic gastric ulcer with pioglitazone, a per-
oxisome proliferator-activated receptor-γ (PPAR-γ)
ligand, resulted in attenuation of gastric injury.4 The
expression of TNF-α and IL-1β in ulcer tissue was
increased, while that of PPAR-γ was decreased. After
treatment with pioglitazone, the expression of TNF-α
and IL-1β was reduced and PPAR-γ was increased in
gastric mucosa. These results confirmed the findings
of Brzozowski et al, who had observed that pioglita-
zone not only decreased the gene expression of TNF-α
and IL-1β in ulcer tissue, but also reduced the plasma
level of TNF-α and IL-1β in rats with acetic acid-
induced ulcers.5 However, an interesting finding by
Lahiri et al is that pioglitazone treatment significantly
upregulated the level of glucocorticoid receptors and
a glucocorticoid receptor antagonist, RU486, inhibited
the effect of pioglitazone on TNF-α and IL-1β during
the ulcer healing process. This interaction between glu-
cocorticoid receptor and PPAR-γ showed that gluco-
corticoid and its receptors played important roles in the
regulation of expression of proinflammatory cytokines
and the consequent healing process of gastric ulcers.
During the gastric ulcer healing process, the pro-
liferation and migration of gastric epithelial cells are
regulated by cytokines and hormones. Using human
gastric ulcer mucosa biopsy samples for analysis of gene
expression of COX-2 and local cytokines, Wu et al
found that H. pylori infection did not affect the expres-
sion of COX-2 and local cytokines in gastric mucosa
while patients taking NSAID had decreased COX-2
levels and delayed healing of gastric ulcer.6 NSAID-
induced inflammatory injury in gastric mucosa is
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known to be mediated by the inhibition of COX and
PGE2. Endogenously generated PGE2 from upregu-
lated COX-2 at the ulcer margin plays an important
role in ulcer healing by various gastric protection 
factors such as proton pump inhibitor, growth factors
and melatonin.7 The inhibition of PGE2 production
by NSAIDs blocks the gastric protection effect and
delays healing. It is clear that PGE2 plays a critical role
in gastric ulcer healing.
In the October 2009 issue of the Journal of the
Chinese Medical Association, Luo et al examined the
effects of dexamethasone on TNF-α-stimulated epithe-
lial cell migration. Their results clearly showed that
TNF-α treatment of RGM-1 rat normal gastric epithe-
lial cells resulted in increased cell migration that was
dependent on COX-2 protein expression and the
secretion of PGE2 in a time-dependent manner. This
TNF-α-stimulated migration was blocked by dexam-
ethasone treatment, with concomitant decreased levels
of COX-2 and PGE2.8 In addition, Luo et al had pre-
viously shown that angiogenesis and the expression 
of basic fibroblast growth factor (bFGF), vascular
endothelial growth factor (VEGF) and PGE2 were
increased in gastric ulcer margin tissues using an acetic
acid-induced rat gastric ulcer model. Dexamethasone
treatment reduced angiogenesis and delayed ulcer
healing together with reducing levels of VEGF and
PGE2.1 Moreover, Luo et al showed that dexametha-
sone treatment resulted in inhibition of ERK1/ERK2
and COX-2 signaling pathways and inhibited the 
epidermal growth factor-stimulated proliferation of
RGM-1 rat gastric epithelial cells.9 A recent study by
Martin et al found that glucocorticoid-inducible pro-
tein annexin-1 was significantly increased in gastric mar-
gins in the ulcer healing process. Annexin-1 knockout
mice had impaired healing response to indomethacin-
induced gastric damage.10 These results together sug-
gest that glucocorticoids may have both positive and
negative regulatory functions in the ulcer healing
process.
Interaction of epithelial, fibroblast and immune cells
and their intercommunication is another important
aspect in gastric ulcer healing. At the same time,
NSAIDs and cytokines also modulate factors that are
involved in tissue remodeling. Iwamoto et al showed
clearly that TNF-α, IL-1β and PGE2 treatment sig-
nificantly increased the expression of urokinase-type
plasminogen activator and its receptor in gastric fibrob-
lasts. The IL-1β-induced increase in urokinase-type
plasminogen activator and its receptor was dose-
dependently inhibited by indomethacin.2 Luo et al
further showed that bFGF stimulated the growth of
RGM-1 gastric epithelial cells and dexamethasone
blocked this bFGF-stimulated signal transduction and
COX-2 expression.3 These results clearly demonstrate
that inhibition of COX-2 by either NSAIDs or gluco-
corticoids can result in reduced levels of PGE2 in the
ulcer area and hinder tissue remodeling and delay ulcer
healing.
In conclusion, gastric ulcer healing is a complicated
process that is regulated by multiple factors. The bal-
ance between ulcer healing promoting factors such as
TNF-α, IL-1β, VEGF and PGE2, and ulcer inhibit-
ing drugs such as NSAIDs and glucocorticoids will
determine the progression or healing of gastric ulcer.
Luo et al’s results8 add to the direct evidence that
glucocorticoids have a negative impact not only on
the proliferation but also on the migration of gastric
epithelial cells. The potential of using glucocorticoid
antagonists in combination with ulcer healing drugs
is worthy of further investigation.
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